BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34923243)

  • 1. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.
    Ragab MA; Elagawany M; Daabees H; Ahmed AF; Awad EM; Billon C; Elgendy B; Abouzid KAM; Kassab SE
    Bioorg Chem; 2022 Feb; 119():105554. PubMed ID: 34923243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
    Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
    Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants.
    Kurtanović N; Tomašević N; Matić S; Mitrović MM; Kostić DA; Sabatino M; Antonini L; Ragno R; Mladenović M
    Eur J Med Chem; 2022 Jan; 227():113869. PubMed ID: 34710747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and bioevaluation of novel 6-(4-Hydroxypiperidino)naphthalen-2-ol-based potential Selective Estrogen Receptor Modulators for breast cancer.
    Jha A; Yadav Y; Naidu AB; Rao VK; Kumar A; Parmar VS; MacDonald WJ; Too CK; Balzarini J; Barden CJ; Cameron TS
    Eur J Med Chem; 2015 Mar; 92():103-14. PubMed ID: 25544690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of estrogen receptor ligands with a 4-heterocycle-4-phenylheptane skeleton.
    Eto R; Misawa T; Noguchi-Yachide T; Ohoka N; Kurihara M; Naito M; Tanaka M; Demizu Y
    Bioorg Med Chem; 2018 May; 26(8):1638-1642. PubMed ID: 29525335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity.
    Zhou HB; Carlson KE; Stossi F; Katzenellenbogen BS; Katzenellenbogen JA
    Bioorg Med Chem Lett; 2009 Jan; 19(1):108-10. PubMed ID: 19014882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
    Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
    Knox A; Kalchschmid C; Schuster D; Gaggia F; Manzl C; Baecker D; Gust R
    Eur J Med Chem; 2020 Apr; 192():112191. PubMed ID: 32169784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
    Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
    J Med Chem; 2001 Mar; 44(7):1072-84. PubMed ID: 11297454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
    Govek SP; Bonnefous C; Julien JD; Nagasawa JY; Kahraman M; Lai AG; Douglas KL; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
    Bioorg Med Chem Lett; 2019 Feb; 29(3):367-372. PubMed ID: 30587451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
    Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
    Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New estrogen receptor antagonists. 3,20-Dihydroxy-19-norpregna-1,3,5(10)-trienes: Synthesis, molecular modeling, and biological evaluation.
    Kuznetsov YV; Levina IS; Scherbakov AM; Andreeva OE; Fedyushkina IV; Dmitrenok AS; Shashkov AS; Zavarzin IV
    Eur J Med Chem; 2018 Jan; 143():670-682. PubMed ID: 29220789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, in silico and biological evaluation of new indole based oxadiazole derivatives targeting estrogen receptor alpha.
    Kaur K; Verma H; Gangwar P; Jangid K; Dhiman M; Kumar V; Jaitak V
    Bioorg Chem; 2024 Jun; 147():107341. PubMed ID: 38593531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
    J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and anti-breast cancer evaluation of new triarylethylene analogs bearing short alkyl- and polar amino-/amido-ethyl chains.
    Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1963-9. PubMed ID: 26972118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents.
    Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
    Eur J Med Chem; 2014 Oct; 86():211-8. PubMed ID: 25164760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents.
    Dube PN; Sakle NS; Dhawale SA; More SA; Mokale SN
    Anticancer Agents Med Chem; 2019; 19(9):1150-1160. PubMed ID: 30848213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of thieno[3',2':5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the estrogen receptor ligands: synthesis, characterization and biological activity.
    Wang X; Sun R; Huang Y; Yan Y; Gao M; Wang DN; Koirala D; Li DW; Hu C
    Med Chem; 2014; 10(8):836-42. PubMed ID: 24773350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.